CUE - Cue Biopharma doses the first patient in trial for CUE-101 in head and neck cancer

Chinnapong/iStock via Getty Images Massachusetts-based clinical-stage Cue Biopharma (CUE) announced the dosing of the first patient in Part B expansion phase of its Phase 1 study for CUE-101 as monotherapy at the recommended Phase 2 dose of 4mg/kg. The multi-center, open-label study is designed to evaluate CUE-101 as a monotherapy in the second line and beyond (2L+) patients with HPV+ (human papillomavirus) head and neck squamous cell carcinoma ((HNSCC)). The trial is expected to enroll up to 20 patients.  In Phase 1a dose-escalation portion of the CUE-101 monotherapy trial, the data supporting the “patient expansion has been encouraging to date,” the company said. Six patients had confirmed stable disease ((SD)) and one patient has achieved a partial response of nearly 50% of tumor reduction. Data supporting the selection of the dose “gives us growing confidence that CUE-101 may provide a potential path forward for a registration-directed clinical trial as a single agent

For further details see:

Cue Biopharma doses the first patient in trial for CUE-101 in head and neck cancer